Astra makes machine learning bet with Benevolent AI deal
Astrazeneca has made another push into artificial intelligence, but admits that it will be some time before it knows whether the technology has helped its drug discovery…
LAM aims to apply methylation cancer testing to blood
The cancer blood testing company Laboratory for Advanced Medicine is ready to compete on price, which might be necessary in a market already thronged with products.
Deals and data in the offing for Oncimmune
Oncimmune is not the only company looking to use the immune system to diagnose cancer. But its growth plans are intense, and it intends to prove the economic benefits of…
Boehringer pushes pipeline progress
The notoriously secretive German pharma company Boehringer Ingelheim has made much of a new drive towards transparency, but there are still things it would rather keep to…
Leviticus Cardio charges towards the market
A tiny Israeli company has beaten some of the biggest medtechs in the world to the wireless charging of heart pumps.
Lundbeck needs deals, but what can it afford?
With few pipeline catalysts this year the pressure is growing on Lundbeck's new chief executive, Deborah Dunsire, to deliver a deal. But the company only has $5bn to…
Bayer holds its nerve as patent cliff approaches
As pressure builds on the German group to explain how it will replace expiring blockbusters, executives lay out a preference for early-stage collaborations and insist…
Caladrius refuses to give up on Tregs for diabetes
After a trial failure last week, Caladrius Biosciences has not abandoned hope for its T regulatory cell therapy in type 1 diabetes, but funding might become a problem.
Novo Nordisk sticks its neck out for a tech that promises oral insulin
A capsule device inspired by the shape of a tortoise’s shell might just be able to deliver proteins orally, and Novo Nordisk is on board. But the tech is still years away…
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.